Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

38
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
38
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.1K
The pathophysiology of pneumonia involves the following steps:
4.1K
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

102
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
102
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.3K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.3K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

1.2K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.2K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Self-testing for five respiratory viruses in adults ≥50 years of age in Germany for longitudinal monitoring of community-acquired acute respiratory infections.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Self-testing for 5 respiratory viruses in adult VACCELERATE volunteers in Germany-a pilot study on multi-pathogen rapid antigen testing to monitor community-acquired acute respiratory infections.

Frontiers in public health·2025
Same author

Invasive Meningococcal Disease in the Post-COVID World: Patterns of Disease Rebound.

Vaccines·2025
Same author

Global epidemiology of serogroup Y invasive meningococcal disease: a literature review.

Epidemiology and infection·2024
Same author

Challenges in assessing the immunization status of adults in Germany-lessons from a population-based VACCELERATE survey on polio vaccination.

Infection·2024
Same author

Real-world impact and effectiveness of MenACWY-TT.

Human vaccines & immunotherapeutics·2023

Related Experiment Video

Updated: Mar 31, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
06:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

2.3K

Pneumococcal serotype evolution in Western Europe.

Myint Tin Tin Htar1, Dina Christopoulou2, Heinz-Josef Schmitt3

  • 1Pfizer Vaccines, Medical Development Group and Scientific Affairs, 23-25 avenue du Dr. Lannelongue, F-75668, Paris, Cedex 14, France. Myint.TinTinHtar@pfizer.com.

BMC Infectious Diseases
|October 16, 2015
PubMed
Summary

Pneumococcal conjugate vaccines (PCVs) have drastically reduced vaccine-type invasive pneumococcal disease (IPD) in children. However, non-vaccine serotypes are emerging, necessitating ongoing surveillance and vaccine strategy evaluation.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.7K
Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

46.8K

Related Experiment Videos

Last Updated: Mar 31, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
06:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

2.3K
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.7K
Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

46.8K

Area of Science:

  • * Microbiology and Immunology
  • * Vaccinology
  • * Epidemiology

Background:

  • * Pneumococcal diseases are a major cause of vaccine-preventable deaths in children globally.
  • * The introduction of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe was followed by higher-valent PCVs (PCV10, PCV13).
  • * This study examines serotype evolution of invasive pneumococcal disease (IPD) post-PCV introduction in Western Europe.

Purpose of the Study:

  • * To describe the evolution of vaccine and non-vaccine serotypes causing IPD.
  • * To analyze the impact of PCV7, PCV10, and PCV13 on serotype distribution.
  • * To inform future pneumococcal vaccination strategies.

Main Methods:

  • * Analysis of publicly available medical publications.
  • * Review of national surveillance system data.
  • * Data collection period: January 2010 to May 2015.

Main Results:

  • * High vaccine uptake led to near disappearance of PCV7 serotypes in children.
  • * Emergence of non-PCV7 serotypes (e.g., 19A, 7F, 3, 1) observed.
  • * Higher-valent PCVs showed rapid reduction of included serotypes; PCV13 impacted 19A, 7F, 1, 6A; PCV10 saw increases in 19A and 3.
  • * Serotype 3 became prevalent in adults; diversity varied by age, vaccine type, and time since introduction.
  • * Emerging non-PCV13 types are generally less invasive.

Conclusions:

  • * Close monitoring of evolving serotypes and vaccination program impact is crucial.
  • * Vaccination strategies require adaptation based on surveillance data.
  • * Emerging serotypes should be considered for future vaccine development.